Optic pathway–hypothalamic glioma (OPHG) can be managed with radiotherapy or radiosurgery, which provide durable local control in many patients. However, late toxicities—vascular, endocrine, visual, oncological, and neurological—have limited broader use. This systematic review and meta-analysis aimed to characterize and quantify the safety profile of radiotherapy and radiosurgery for OPHG and to explore clinically relevant modifiers of treatment-related toxicity.
The investigators searched PubMed, Scopus, Web of Science, Embase, Cochrane, Google Scholar, and ClinicalTrials.gov from inception through 1 June 2026. Eligible studies were nonrandomized reports that provided safety outcomes after radiotherapy or radiosurgery for OPHG. A total of 35 studies met inclusion criteria; 31 of these supplied event-level data that could be pooled for at least one quantitative safety outcome.
Pooled proportions were estimated using random-effects binomial-normal generalized linear mixed-effects models. For sparse comparative analyses, exact conditional models were applied. The review included supplementary sensitivity, influence, subgroup, meta-regression, and diagnostic analyses, as reported in the article’s supplementary figures. Risk-of-bias assessments were performed and are provided in the supplementary materials.
Across the included studies the pooled incidence of any treatment-related toxicity was 8.46% (95% CI, 1.37–38.01%). This pooled estimate reflects heterogeneity across study designs, follow-up durations, and reporting detail.
Vasculopathy was identified as a major quantifiable late adverse event. The pooled incidence of vasculopathy was 9.44% (95% CI, 5.22–16.49%). The authors highlight vascular events among the principal safety concerns after radiotherapy for OPHG and recommend prolonged vascular surveillance in treated patients.
Secondary neoplasms attributable to radiotherapy were reported with a pooled incidence of 5.41% (95% CI, 2.23–12.53%). When a strict definition limited events to overtly malignant secondary tumors, the pooled estimate decreased to 2.83%. The distinction between all secondary neoplastic events and strictly malignant secondary tumors materially affected pooled rates.
Incident endocrinopathy had the highest pooled estimate among the safety outcomes reported: 21.19% (95% CI, 4.72–59.31%). The authors noted that endocrinopathy incidence increased with longer follow-up, underscoring the time-dependent nature of some late radiation effects and the need for extended endocrine surveillance after treatment.
Treatment-related visual toxicity was pooled at 2.26%. Radiation-related mortality was uncommon, with a pooled rate of 0.59%. Radiation necrosis, severe toxicity, and treatment-attributed neurocognitive toxicity were infrequently or sparsely reported across the studies, limiting quantitative synthesis for those outcomes.
Late toxicity after radiotherapy for OPHG was heterogeneous across the literature. Several specific outcomes—radiation necrosis, severe adverse events, and neurocognitive decline attributed to treatment—were sparsely reported, which constrains meta-analytic precision for those endpoints. The included studies were nonrandomized; differences in radiation modalities, dose, volume, patient selection, and follow-up duration contributed to heterogeneity.
Given these findings, the authors recommend individualized treatment decisions that weigh potential benefits against the documented risks of endocrinopathy, vasculopathy, and secondary neoplasms. They also advise prolonged vascular, endocrine, visual, and oncological surveillance for patients treated with radiotherapy or radiosurgery for OPHG.
This systematic review and meta-analysis found that late toxicity after radiotherapy for OPHG is variable but that endocrine dysfunction, vascular complications, and secondary tumors represent the principal quantifiable safety concerns. Visual toxicity and radiation-related mortality were reported less frequently. The authors call for further prospective evaluation of contemporary radiation techniques and extended follow-up to better define time-dependent risks.
Note: All data, pooled estimates, confidence intervals, and methodological details above are drawn directly from the source systematic review and meta-analysis. The review was posted on medRxiv on August 21, 2026, and supplementary datasets, risk-of-bias assessments, and analytic outputs are available in the article’s supplementary materials as described by the authors.